Breaking News Instant updates and real-time market news.

IRWD

Ironwood

$15.88

0.48 (3.12%)

07:32
10/03/16
10/03
07:32
10/03/16
07:32

Ironwood announces U.S. availability of Zurampic 200mg tablets

Ironwood Pharmaceuticals announced that ZURAMPIC is now available in pharmacies throughout the United States. ZURAMPIC is approved as a once-daily oral tablet to be taken in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia - high serum uric acid levels in the blood - associated with gout in patients who have not achieved target sUA levels with an XOI alone. ZURAMPIC is not recommended for the treatment of asymptomatic hyperuricemia and should not be used as monotherapy. The safety and efficacy of ZURAMPIC were established in three Phase III, multicenter, randomized, double-blind, 12-month, placebo-controlled clinical studies in adult patients with hyperuricemia and gout. In two of the trials, ZURAMPIC was studied in combination with allopurinol and in a third trial was studied in combination with febuxostat. Most common adverse reactions with ZURAMPIC in the clinical trials were headache, influenza, blood creatinine increased, and gastroesophageal reflux disease.

  • 06

    Nov

IRWD Ironwood
$15.88

0.48 (3.12%)

04/06/16
04/06/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CRH (CRH) upgraded to Overweight at JPMorgan by analyst Elodie Rall, who views the valuation as attractive and sees limited risk to estimates. 2. Ironwood (IRWD) upgraded to Outperform at Cowen citing the company's pipeline and ex-U.S. royalties as well as U.S. co-marketing agreements leaving room for growth. 3. Owens-Illinois (OI) upgraded to Buy at Citi with analyst Anthony Pettinari citing valuation and a low bar set by management for 2016. 4. Pennsylvania REIT (PEI) upgraded to Outperform at Boenning & Scattergood by analyst Floris van Dijkum, who believes Pennsylvania REIT's discounted valuation is unwarranted given significant acceleration in 2018 NOI growth. van Dijkum expects the company to continue to reduce leverage by selling other non-core assets and make development progress on the Fashion Outlets of Philadelphia. 5. Cisco (CSCO) upgraded to Neutral at JPMorgan with analyst Rod Hall saying the company's 3.8% dividend yield is "compelling in the midst of current market volatility." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/16
JPMS
04/26/16
NO CHANGE
JPMS
Ironwood Linzess safety concerns overblown, says JPMorgan
04/26/16
COWN
04/26/16
NO CHANGE
COWN
Outperform
Ironwood short report does not discuss any new information, says Cowen
Cowen analyst Boris Peaker,commented on the short report on Ironwood (IRWD) issued by Phase Five Research and said it doesn't appear to discuss any new data. Peaker said the analysis ignores the co-morbidities of patients that are on Linzess, which has been in 2M patients, many with significant other illnesses and on multiple other background therapies. Additionally, the report overlooked the acquisition of Zurampic today from AstraZeneca (AZN) that was favorably structured with a $100M upfront payment to Ironwood, the analyst said. Peaker said feedback on Linzess from consultants at Cowen's Healthcare Conference was positive and reiterates his Outperform rating.
04/27/16
UBSW
04/27/16
NO CHANGE
Target $8
UBSW
Sell
Ironwood had no new safety concerns with Linzess, says UBS
UBS said the FDA had no new safety concerns and there were no regulatory actions required for Ironwood's Linzess drug. The firm expects the noise from yesterday's short report, which suggested the FDA had issues with Linzess, to subside as the safety concerns pointed to were not justified. UBS acknowledges they have not given much credit for the company's pipeline, but they prefer to stay on the sidelines and take a "wait and see" attitude. UBS maintained its Sell rating and $8 price target on Ironwood shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.